Fintel reports that on February 3, 2025, Redburn Atlantic upgraded their outlook for DexCom (NasdaqGS:DXCM) from Neutral to ...

DexCom (NASDAQ:DXCM) shares received an optimistic update from Redburn-Atlantic, with analyst Issie Kirby (NYSE:KEX) upgrading the stock from Neutral to Buy and increasing the price target to $115 ...

DXCM's top line reflects strong demand for its CGM sensors. International expansion is also driving sales higher. Gross margin reflects inventory damage.

The bull market of the past year or more has reinvigorated investors' interest across a range of industries, and the ...

On Monday, DexCom Inc (DXCM) stock saw a decline, ending the day at $87.53 which represents a decrease of $-1.22 or -1.37% from the prior close of $88.75. The stock opened at $88.58 and touched a low ...

Medical device specialist DexCom (NASDAQ: DXCM) has substantially underperformed the market over the trailing-12-month period ...

DexCom (NASDAQ:DXCM) shares popped 6% premarket on Monday after the company set its financial forecast for 2025, projecting adjusted gross profit margin of around 64% – 65% on revenue of $4.60B ...

DexCom, Inc. DXCM is well-poised for growth in ... company’s shares have lost 31.2% in the past six months against the industry’s 0.6% growth. The S&P 500 Index has jumped 3.8% in the same ...

sending the medical device maker's shares up nearly 6% premarket. Dexcom's shares had fallen nearly 37% last year, largely due to a slump in July after the company slashed its annual revenue ...

Dexcom (DXCM – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst on January 13. Analyst Mike Kratky from Leerink Partners maintained a Buy rating on the ...

Geneos Wealth Management Inc. lessened its position in shares of DexCom, Inc. (NASDAQ:DXCM – Free Report) by 2.6% in the ...